Robert P. Smith

Learn More
Current techniques for investigating patients with suspected sleep disordered breathing are inadequate. Not only are many of the tests expensive, but they are also cumbersome and many centres require these investigations to be performed in the sleep laboratory. At the heart of the problem is the diYculty in identifying and quantifying the spectrum of(More)
BACKGROUND AND OBJECTIVES Gefitinib (IRESSA, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, has been approved in several countries for the treatment of advanced non-small-cell lung cancer. Preclinical studies were conducted to determine the cytochrome P450 (CYP) isoenzymes involved in the metabolism of gefitinib and to evaluate the(More)
PURPOSE Gefitinib is an oral agent that inhibits the tyrosine kinase of the epidermal growth factor receptor. In phase I trials gefitinib was well tolerated and antitumor activity was seen in pretreated non-small-cell lung cancer (NSCLC) patients. Preclinical studies indicated enhanced effects when gefitnib was added to carboplatin or paclitaxel. This pilot(More)
PURPOSE This dose-escalating study investigated the toxicity, pharmacokinetics, and efficacy of the novel direct-acting antifolate ZD9331, given as a 5-day i.v. infusion every 3 weeks. EXPERIMENTAL DESIGN Forty-five patients with refractory solid malignancies received ZD9331, which was escalated from 0.125 mg/m(2)/day. RESULTS Dose-limiting grade 4(More)
Despite improvements in conventional treatment, patients with advanced non-small-cell lung cancer (NSCLC) have a poor prognosis, leaving a significant unmet need for novel treatments. One such novel, biologically targeted agent is the orally active epidermal growth factor receptor tyrosine kinase inhibitor gefitinib. This open-label pilot trial investigated(More)
The antiarrhythmic and cardioprotective effect of increasing gap junction intercellular communication during ischemia/reperfusion injury has not been studied. The antiarrhythmic peptide rotigaptide (previously ZP123), which maintains gap junction intercellular communication, was tested in dogs subjected to a 60-min coronary artery occlusion and 4 h of(More)
PURPOSE To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent malignant glioma. PATIENTS AND METHODS Gefitinib and sirolimus were administered(More)
We have observed the Bose-Einstein condensation of an atomic gas in the (quasi)uniform three-dimensional potential of an optical box trap. Condensation is seen in the bimodal momentum distribution and the anisotropic time-of-flight expansion of the condensate. The critical temperature agrees with the theoretical prediction for a uniform Bose gas. The(More)
We study the stability of a thermal (39)K Bose gas across a broad Feshbach resonance, focusing on the unitary regime, where the scattering length a exceeds the thermal wavelength λ. We measure the general scaling laws relating the particle-loss and heating rates to the temperature, scattering length, and atom number. Both at unitarity and for positive a<<λ(More)
PURPOSE ZD9331 is a novel, direct-acting antifolate cytotoxic that does not require polyglutamation for activity, and is a specific thymidylate synthase inhibitor. This Phase I trial aimed to determine the maximum tolerated dose of ZD9331, given as a 30-min i.v. infusion on days 1 and 8 of a 21-day cycle. Pharmacokinetic parameters and tumor response were(More)